Gefitinib plus chemotherapy expands treatment toolbox for EGFR-mutated NSCLC
21 Oct 2019
byJairia Dela Cruz
Combining gefitinib with pemetrexed and carboplatin confers significant survival benefits in patients with nonsmall-cell lung cancer (NSCLC) that harbour an epidermal growth factor receptor (EGFR) mutation, extending progressive-free and overall survival although at the expense of increased toxicity, according to the results of an open-label phase III trial.